标签归档：ome

Z-VAD(OMe)-FMK(Synonyms: Z-Val-Ala-Asp(OMe)-FMK)

发表于由

上海金畔生物科技有限公司为生命科学和医药研发人员提供生物活性分子抑制剂、激动剂、特异性抑制剂、化合物库、重组蛋白，专注于信号通路和疾病研究领域。

Z-VAD(OMe)-FMK (Synonyms: Z-Val-Ala-Asp(OMe)-FMK) 纯度: ≥98.0%

Z-VAD(OMe)-FMK (Z-Val-Ala-Asp(OMe)-FMK) 是一种不可逆的 pan-caspase 抑制剂。Z-VAD(OMe)-FMK 是泛素 C 末端水解酶 L1 (UCHL1) 抑制剂。Z-VAD(OMe)-FMK 通过靶向 UCHL1 活性位点对 UCHL1 进行不可逆地修饰。

Z-VAD(OMe)-FMK(Synonyms: Z-Val-Ala-Asp(OMe)-FMK)

Z-VAD(OMe)-FMK Chemical Structure

CAS No. : 187389-52-2

规格 价格 是否有货 数量
10 mM * 1 mL in DMSO ￥1748 In-stock
1 mg ￥650 In-stock
5 mg ￥1700 In-stock
10 mg ￥2700 In-stock
50 mg   询价  
100 mg   询价  

* Please select Quantity before adding items.

Z-VAD(OMe)-FMK 相关产品

•相关化合物库:

  • Covalent Screening Library Plus
  • Bioactive Compound Library Plus
  • Apoptosis Compound Library
  • Anti-Cancer Compound Library
  • Peptidomimetic Library
  • Covalent Screening Library

生物活性

Z-VAD(OMe)-FMK (Z-Val-Ala-Asp(OMe)-FMK) is a cell-permeable and irreversible pan-caspase inhibitor[1]. Z-VAD(OMe)-FMK is an ubiquitin carboxy-terminal hydrolase L1 (UCHL1) inhibitor. Z-VAD(OMe)-FMK irreversibly modifies UCHL1 by targeting the active site of UCHL1[2].

IC50 & Target[1]

Caspase

 

体外研究
(In Vitro)

Z-VAD(OMe)-FMK (Z-Val-Ala-Asp(OMe)-FMK) is a broad-spectrum caspase inhibitor, has been shown to inhibit the intracellular activation of caspase-like proteases. The injection of Z-VAD(OMe)-FMK suppresses the caspase-3 activity in lung tissues, and significantly decreases the number of terminal dUTP nick-end labeling-positive cells[1]. Z-VAD(OMe)-FMK effectively inhibits UCHL1’s reaction with hemagglutinin-tagged ubiquitin vinylmethyl ester (HA-UbVME) at the concentration of 100 μM[2]. Z-VAD(OMe)-FMK is administered intraperitoneally at 1 hour before and 6 hours after SAH. Expression of caspase-3 and positive TUNEL is examined as markers for apoptosis. Z-VAD(OMe)-FMK suppresses TUNEL and caspase-3 staining in endothelial cells, decreases caspase-3 activation, reduces BBB permeability, relieves vasospasm, abolishes brain edema, and improves neurological outcome[3]. Z-VAD(OMe)-FMK is a cell-permeable caspase inhibitor, efficiently blocks cell death induced by SMN deficiency[4].

上海金畔生物科技有限公司 has not independently confirmed the accuracy of these methods. They are for reference only.
体内研究
(In Vivo)

The survival rate of mice is prolonged significantly by the injection of Z-VAD(OMe)-FMK (Z-Val-Ala-Asp(OMe)-FMK). All mice succumbed to LPS within 30 hours. By contrast, the mice treated with Z-VAD(OMe)-FMK survive significantly longer and 27% of the mice survived more than 7 days[1].

上海金畔生物科技有限公司 has not independently confirmed the accuracy of these methods. They are for reference only.
分子量

467.49

Formula

C22H30FN3O7
CAS 号

187389-52-2
Sequence

Z-Val-Ala-Asp(OMe)-FMK
Sequence Shortening

ZVA-D(OMe)-FMK
运输条件

Room temperature in continental US; may vary elsewhere.
储存方式
Powder -80°C 2 years
-20°C 1 year
In solvent -80°C 6 months
-20°C 1 month
溶解性数据
In Vitro: 

DMSO : 100 mg/mL (213.91 mM; Need ultrasonic)

配制储备液
浓度 溶剂体积 质量 1 mg 5 mg 10 mg
1 mM 2.1391 mL 10.6954 mL 21.3908 mL
5 mM 0.4278 mL 2.1391 mL 4.2782 mL
10 mM 0.2139 mL 1.0695 mL 2.1391 mL

*

请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。
储备液的保存方式和期限：-80°C, 6 months; -20°C, 1 month。-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。

In Vivo:

请根据您的实验动物和给药方式选择适当的溶解方案。以下溶解方案都请先按照 In Vitro 方式配制澄清的储备液，再依次添加助溶剂：

——为保证实验结果的可靠性，澄清的储备液可以根据储存条件，适当保存；体内实验的工作液，建议您现用现配，当天使用； 以下溶剂前显示的百
分比是指该溶剂在您配制终溶液中的体积占比；如在配制过程中出现沉淀、析出现象，可以通过加热和/或超声的方式助溶

  • 1.

    请依序添加每种溶剂： 5% DMSO    40% PEG300    5% Tween-80    50% saline

    Solubility: ≥ 2.62 mg/mL (5.60 mM); Clear solution

  • 2.

    请依序添加每种溶剂： 5% DMSO    95% (20% SBE-β-CD in saline)

    Solubility: ≥ 2.62 mg/mL (5.60 mM); Clear solution

  • 3.

    请依序添加每种溶剂： 10% DMSO    40% PEG300    5% Tween-80    45% saline

    Solubility: ≥ 2.5 mg/mL (5.35 mM); Clear solution

    此方案可获得 ≥ 2.5 mg/mL (5.35 mM，饱和度未知) 的澄清溶液。

    以 1 mL 工作液为例，取 100 μL 25.0 mg/mL 的澄清 DMSO 储备液加到 400 μL PEG300 中，混合均匀；向上述体系中加入50 μL Tween-80，混合均匀；然后继续加入 450 μL生理盐水定容至 1 mL。

    将 0.9 g 氯化钠，完全溶解于 100 mL ddH₂O 中，得到澄清透明的生理盐水溶液

  • 4.

    请依序添加每种溶剂： 10% DMSO    90% (20% SBE-β-CD in saline)

    Solubility: ≥ 2.5 mg/mL (5.35 mM); Clear solution

    此方案可获得 ≥ 2.5 mg/mL (5.35 mM，饱和度未知) 的澄清溶液。

    以 1 mL 工作液为例，取 100 μL 25.0 mg/mL 的澄清 DMSO 储备液加到 900 μL 20% 的 SBE-β-CD 生理盐水水溶液中，混合均匀。

    将 2 g 磺丁基醚 β-环糊精加入 5 mL 生理盐水中，再用生理盐水定容至 10 mL，完全溶解，澄清透明
  • 5.

    请依序添加每种溶剂： 10% DMSO    90% corn oil

    Solubility: ≥ 2.5 mg/mL (5.35 mM); Clear solution

    此方案可获得 ≥ 2.5 mg/mL (5.35 mM，饱和度未知) 的澄清溶液，此方案不适用于实验周期在半个月以上的实验。

    以 1 mL 工作液为例，取 100 μL 25.0 mg/mL 的澄清 DMSO 储备液加到 900 μL玉米油中，混合均匀。

  • 6.

    请依序添加每种溶剂： 1% DMSO    99% saline

    Solubility: ≥ 0.52 mg/mL (1.11 mM); Clear solution

*以上所有助溶剂都可在 上海金畔生物科技有限公司 网站选购。
参考文献

  • [1]. Kawasaki M, et al. Protection from lethal apoptosis in lipopolysaccharide-induced acute lung injury in mice by a caspaseinhibitor. Am J Pathol. 2000 Aug;157(2):597-603.

    [2]. Davies CW, et al. The co-crystal structure of ubiquitin carboxy-terminal hydrolase L1 (UCHL1) with a tripeptide fluoromethyl ketone (Z-VAE(OMe)-FMK). Bioorg Med Chem Lett. 2012 Jun 15;22(12):3900-4.

    [3]. Park S, et al. Neurovascular protection reduces early brain injury after subarachnoid hemorrhage. Stroke. 2004 Oct;35(10):2412-7.

    [4]. Ilangovan R, et al. Inhibition of apoptosis by Z-VAD-fmk in SMN-depleted S2 cells. J Biol Chem. 2003 Aug 15;278(33):30993-9.
Cell Assay
[4]

PCR products containing coding sequences for the dSMN (forward primer: 5′-TAA TAC GAC TCA CTA TAG GG AAG ACG TAC GAC GAG TCG-3′; and reverse primer: 5′-TAA TAC GAC TCA CTA TAG GG GTG GTG CTG GCT TCT TTC-3′; product length, 601bps; bold and italics letters represent T7 promoter sequences) and control Drosophila Presenilin (dPsn) gene (forward primer: 5′-TAA TAC GAC TCA CTA TAG GG TG GCT GCT GTC AAT CTC-3′; and reverse primer: 5′-TAA TAC GAC TCA CTA TAG GG CGA TAG CAA CGC TTC TTG-3′; product length: 543bps) are obtained and gel-purified. Double-stranded RNAs (dsRNA) are generated by transcription with Ribomax T7 Transcription kit and digested with Rnase-free DNase. The dsRNA products are ethanol precipitated and annealed by incubation at 65°C for 30 min and then slowly allowed to cool at room temperature. The annealed dsRNA products are analyzed on a 1% agaorse gel to ensure the majority of dsRNA existed as a single band. The dsRNA (2 μg) and/or plasmid DNAs (2 μg) are introduced into cells by using Cellfectin. Caspase inhibition is achieved by using 50 μM of Z-VAD(OMe)-FMK in the culture medium[4].

上海金畔生物科技有限公司 has not independently confirmed the accuracy of these methods. They are for reference only.
Animal Administration
[1][3]

Mice[1]
Mice used in this study are 5- to 6-week-old (20 to 22 g) ICR males. Mice are injected with 30 mg/kg LPS from E. coli serotype O111:B4 through the tail vein. A single intravenous injection of Z-VAD(OMe)-FMK (0.25 mg) is made 15 minutes before LPS injection, followed by three intravenous injections of Z-VAD(OMe)-FMK (0.1 mg each) per hour. Control mice are injected with the same volume of 1% DMSO in sterile saline.
Rats[3]
Male Sprague-Dawley rats weighing 300 to 350 g are anesthetized with α-chloralose (40 mg/kg IP) and urethane (400 mg/kg IP). Animals are intubated, and respiration is maintained with a small animal respirator. Rectal temperature is maintained at 37±0.5°C with a heating pad. The left external carotid artery is isolated and a 4.0 monofilament nylon suture is inserted through the internal carotid artery to perforate the middle cerebral artery. SAH is confirmed at autopsy in each rat. Sham-operated rats underwent the same procedures except that the suture is withdrawn after resistance is felt. Z-VAD(OMe)-FMK (50 μM per 0.3 mL) is injected intraperitoneally at 1 hour before and 6 hours after SAH induction. In vehicle group, rats underwent SAH induction and are treated with the same volume of vehicle (DMSO diluted in physiological buffer solution). No treatment is applied in sham-operated animals.

上海金畔生物科技有限公司 has not independently confirmed the accuracy of these methods. They are for reference only.
参考文献

  • [1]. Kawasaki M, et al. Protection from lethal apoptosis in lipopolysaccharide-induced acute lung injury in mice by a caspaseinhibitor. Am J Pathol. 2000 Aug;157(2):597-603.

    [2]. Davies CW, et al. The co-crystal structure of ubiquitin carboxy-terminal hydrolase L1 (UCHL1) with a tripeptide fluoromethyl ketone (Z-VAE(OMe)-FMK). Bioorg Med Chem Lett. 2012 Jun 15;22(12):3900-4.

    [3]. Park S, et al. Neurovascular protection reduces early brain injury after subarachnoid hemorrhage. Stroke. 2004 Oct;35(10):2412-7.

    [4]. Ilangovan R, et al. Inhibition of apoptosis by Z-VAD-fmk in SMN-depleted S2 cells. J Biol Chem. 2003 Aug 15;278(33):30993-9.

所有产品仅用作科学研究或药证申报，我们不为任何个人用途提供产品和服务

Z-IETD-FMK(Synonyms: Z-IE(OMe)TD(OMe)-FMK)

发表于由

上海金畔生物科技有限公司为生命科学和医药研发人员提供生物活性分子抑制剂、激动剂、特异性抑制剂、化合物库、重组蛋白，专注于信号通路和疾病研究领域。

Z-IETD-FMK (Synonyms: Z-IE(OMe)TD(OMe)-FMK) 纯度: ≥98.0%

Z-IETD-FMK (Z-IE(OMe)TD(OMe)-FMK) 是一种具有细胞渗透作用的选择性 caspase-8 抑制剂。Z-IETD-FMK 也是颗粒酶 B (granzyme B) 抑制剂。

Z-IETD-FMK(Synonyms: Z-IE(OMe)TD(OMe)-FMK)

Z-IETD-FMK Chemical Structure

CAS No. : 210344-98-2

规格 价格 是否有货 数量
10 mM * 1 mL in DMSO ￥4321 In-stock
1 mg ￥1400 In-stock
5 mg ￥3000 In-stock
10 mg   询价  
50 mg   询价  

* Please select Quantity before adding items.

Z-IETD-FMK 相关产品

•相关化合物库:

  • Bioactive Compound Library Plus
  • Peptidomimetic Library
  • Peptide Library

生物活性

Z-IETD-FMK (Z-IE(OMe)TD(OMe)-FMK) is a selective and cell permeable caspase-8 inhibitor[1]. Z-IETD-FMK is also a granzyme B inhibitor[5].

IC50 & Target[1]

Caspase-8

 

体外研究
(In Vitro)

Z-IETD-FMK causes full inhibition only of the proapoptotic effect of TNFα with an IC50 of 0.46 μM[1]. Z-IETD-FMK and Z-VAD-FMK at non-toxic doses are found to be immunosuppressive and inhibit human T cell proliferation induced by mitogens and IL-2. They are shown to block NF-κB in activated primary T cells, but have little inhibitory effect on the secretion of IL-2 and IFN-γ during T cell activation[2]. Z-IETD-FMK inhibits the cleavage of caspase-8 and only partially inhibits the cleavage of caspase-3 and PARP. Z-IETD-FMK can prevent the execution of apoptosis in retinal cells exposed to different apoptotic stimuli[3].

上海金畔生物科技有限公司 has not independently confirmed the accuracy of these methods. They are for reference only.
体内研究
(In Vivo)

Pharmacological inhibition of caspase-8 by z-IETD-FMK robustly reduces tumour outgrowth and this is closely associated with a reduction in the release of pro-inflammatory cytokines, IL-6, TNF-α, IL-18, IL-1α, IL-33, but not IL-1β. Furthermore, inhibition of caspase-8 reduces the recruitment of innate suppressive cells, such as myeloid-derived suppressor cells, but not of regulatory T cells to lungs of tumour-bearing mice[4].

上海金畔生物科技有限公司 has not independently confirmed the accuracy of these methods. They are for reference only.
分子量

654.68

Formula

C30H43FN4O11
CAS 号

210344-98-2
Sequence

Z-Ile-Glu-Thr-Asp-FMK
Sequence Shortening

ZIETDFMK
运输条件

Room temperature in continental US; may vary elsewhere.
储存方式
Powder -80°C 2 years
-20°C 1 year
In solvent -80°C 6 months
-20°C 1 month
溶解性数据
In Vitro: 

DMSO : 41.67 mg/mL (63.65 mM; Need ultrasonic)

配制储备液
浓度 溶剂体积 质量 1 mg 5 mg 10 mg
1 mM 1.5275 mL 7.6373 mL 15.2746 mL
5 mM 0.3055 mL 1.5275 mL 3.0549 mL
10 mM 0.1527 mL 0.7637 mL 1.5275 mL

*

请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。
储备液的保存方式和期限：-80°C, 6 months; -20°C, 1 month。-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。

In Vivo:

请根据您的实验动物和给药方式选择适当的溶解方案。以下溶解方案都请先按照 In Vitro 方式配制澄清的储备液，再依次添加助溶剂：

——为保证实验结果的可靠性，澄清的储备液可以根据储存条件，适当保存；体内实验的工作液，建议您现用现配，当天使用； 以下溶剂前显示的百
分比是指该溶剂在您配制终溶液中的体积占比；如在配制过程中出现沉淀、析出现象，可以通过加热和/或超声的方式助溶

  • 1.

    请依序添加每种溶剂： 10% DMSO    40% PEG300    5% Tween-80    45% saline

    Solubility: ≥ 2.08 mg/mL (3.18 mM); Clear solution

    此方案可获得 ≥ 2.08 mg/mL (3.18 mM，饱和度未知) 的澄清溶液。

    以 1 mL 工作液为例，取 100 μL 20.8 mg/mL 的澄清 DMSO 储备液加到 400 μL PEG300 中，混合均匀；向上述体系中加入50 μL Tween-80，混合均匀；然后继续加入 450 μL生理盐水定容至 1 mL。

    将 0.9 g 氯化钠，完全溶解于 100 mL ddH₂O 中，得到澄清透明的生理盐水溶液

  • 2.

    请依序添加每种溶剂： 10% DMSO    90% (20% SBE-β-CD in saline)

    Solubility: ≥ 2.08 mg/mL (3.18 mM); Clear solution

    此方案可获得 ≥ 2.08 mg/mL (3.18 mM，饱和度未知) 的澄清溶液。

    以 1 mL 工作液为例，取 100 μL 20.8 mg/mL 的澄清 DMSO 储备液加到 900 μL 20% 的 SBE-β-CD 生理盐水水溶液中，混合均匀。

    将 2 g 磺丁基醚 β-环糊精加入 5 mL 生理盐水中，再用生理盐水定容至 10 mL，完全溶解，澄清透明
  • 3.

    请依序添加每种溶剂： 10% DMSO    90% corn oil

    Solubility: ≥ 2.08 mg/mL (3.18 mM); Clear solution

    此方案可获得 ≥ 2.08 mg/mL (3.18 mM，饱和度未知) 的澄清溶液，此方案不适用于实验周期在半个月以上的实验。

    以 1 mL 工作液为例，取 100 μL 20.8 mg/mL 的澄清 DMSO 储备液加到 900 μL玉米油中，混合均匀。

*以上所有助溶剂都可在 上海金畔生物科技有限公司 网站选购。
参考文献

  • [1]. Cowburn AS, et al. z-VAD-fmk augmentation of TNF alpha-stimulated neutrophil apoptosis is compound specific and does not involve the generation of reactive oxygen species.

    [2]. Lawrence CP, et al. Suppression of human T cell proliferation by the caspase inhibitors, z-VAD-FMK and z-IETD-FMK is independent of their caspase inhibition properties. Toxicol Appl Pharmacol. 2012 Nov 15;265(1):103-12.

    [3]. Tezel G, et al. Inhibition of caspase activity in retinal cell apoptosis induced by various stimuli in vitro. Invest Ophthalmol Vis Sci. 1999 Oct;40(11):2660-7.

    [4]. Terlizzi M, et al. Pharmacological inhibition of caspase-8 limits lung tumour outgrowth. Br J Pharmacol. 2015 Aug;172(15):3917-28.

    [5]. Yang J, et al. Granzyme B Is an Essential Mediator in CD8+ T Cell Killing of Theileria parva-Infected Cells.Infect Immun. 2018 Dec 19;87(1). pii: e00386-18.
Cell Assay
[2]

T cell proliferation following mitogen stimulation is determined using [3H]-thymidine incorporation. In brief, PBMCs or purified T cells are seeded at 1×106 cells/mL in 96 well plates and stimulated with either PHA (5 μg/mL or co-stimulated with anti-CD3 mAb (5 μg/mL) and anti-CD28 mAb (2.5 μg/mL) in the presence or absence of caspase inhibitor Z-IETD-FMK. The cells are cultured for 72 h with the last 16 h pulsed with [[3H]-labelled methyl-thymidine (0.037 MBq) prior to harvest onto glass fibre filter mats using a Tomtec automated multi-well harvester[2].

上海金畔生物科技有限公司 has not independently confirmed the accuracy of these methods. They are for reference only.
Animal Administration
[4]

Mice: Mice are divided into three groups: (1) naive, non-treated, mice; (2) CTR (control), i.t. instilled with NMU; and (3) lung cancer-bearing mice treated with Z-IETD-FMK (0.5 μg per mouse). The involvement of caspase-8 in lung cancer development is the determined at different time points (3, 7 and 28 days)[4].

上海金畔生物科技有限公司 has not independently confirmed the accuracy of these methods. They are for reference only.
参考文献

  • [1]. Cowburn AS, et al. z-VAD-fmk augmentation of TNF alpha-stimulated neutrophil apoptosis is compound specific and does not involve the generation of reactive oxygen species.

    [2]. Lawrence CP, et al. Suppression of human T cell proliferation by the caspase inhibitors, z-VAD-FMK and z-IETD-FMK is independent of their caspase inhibition properties. Toxicol Appl Pharmacol. 2012 Nov 15;265(1):103-12.

    [3]. Tezel G, et al. Inhibition of caspase activity in retinal cell apoptosis induced by various stimuli in vitro. Invest Ophthalmol Vis Sci. 1999 Oct;40(11):2660-7.

    [4]. Terlizzi M, et al. Pharmacological inhibition of caspase-8 limits lung tumour outgrowth. Br J Pharmacol. 2015 Aug;172(15):3917-28.

    [5]. Yang J, et al. Granzyme B Is an Essential Mediator in CD8+ T Cell Killing of Theileria parva-Infected Cells.Infect Immun. 2018 Dec 19;87(1). pii: e00386-18.

所有产品仅用作科学研究或药证申报，我们不为任何个人用途提供产品和服务

2′-OMe-A(Bz) Phosphoramidite

发表于由

上海金畔生物科技有限公司为生命科学和医药研发人员提供生物活性分子抑制剂、激动剂、特异性抑制剂、化合物库、重组蛋白，专注于信号通路和疾病研究领域。

2′-OMe-A(Bz) Phosphoramidite  纯度: 98.59%

2′-OMe-A(Bz) Phosphoramidite 是一种修饰过的亚磷酰胺单体，可用于寡核苷酸的合成。

2

2′-OMe-A(Bz) Phosphoramidite Chemical Structure

CAS No. : 110782-31-5

规格 价格 是否有货 数量
100 mg ￥500 In-stock
200 mg   询价  
500 mg   询价  

* Please select Quantity before adding items.

2′-OMe-A(Bz) Phosphoramidite 相关产品

•相关化合物库:

  • Bioactive Compound Library Plus
  • Anti-Infection Compound Library
  • Cell Cycle/DNA Damage Compound Library
  • Anti-Cancer Compound Library
  • Anti-Aging Compound Library
  • Reprogramming Compound Library
  • Nucleotide Compound Library
  • Anti-Lung Cancer Compound Library
  • Anti-Blood Cancer Compound Library
  • Anti-Cancer Metabolism Compound Library

生物活性

2′-OMe-A(Bz) Phosphoramidite is a modified phosphoramidite monomer, which can be used for the oligonucleotide synthesis.

分子量

887.96

Formula

C48H54N7O8P
CAS 号

110782-31-5
运输条件

Room temperature in continental US; may vary elsewhere.
储存方式

4°C, protect from light

*In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)
溶解性数据
In Vitro: 

DMSO : 100 mg/mL (112.62 mM; Need ultrasonic)

配制储备液
浓度 溶剂体积 质量 1 mg 5 mg 10 mg
1 mM 1.1262 mL 5.6309 mL 11.2618 mL
5 mM 0.2252 mL 1.1262 mL 2.2524 mL
10 mM 0.1126 mL 0.5631 mL 1.1262 mL

*

请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。
储备液的保存方式和期限：-80°C, 6 months; -20°C, 1 month (protect from light)。-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。

In Vivo:

请根据您的实验动物和给药方式选择适当的溶解方案。以下溶解方案都请先按照 In Vitro 方式配制澄清的储备液，再依次添加助溶剂：

——为保证实验结果的可靠性，澄清的储备液可以根据储存条件，适当保存；体内实验的工作液，建议您现用现配，当天使用； 以下溶剂前显示的百
分比是指该溶剂在您配制终溶液中的体积占比；如在配制过程中出现沉淀、析出现象，可以通过加热和/或超声的方式助溶

  • 1.

    请依序添加每种溶剂： 10% DMSO    90% corn oil

    Solubility: ≥ 2.5 mg/mL (2.82 mM); Clear solution

    此方案可获得 ≥ 2.5 mg/mL (2.82 mM，饱和度未知) 的澄清溶液，此方案不适用于实验周期在半个月以上的实验。

    以 1 mL 工作液为例，取 100 μL 25.0 mg/mL 的澄清 DMSO 储备液加到 900 μL玉米油中，混合均匀。

*以上所有助溶剂都可在 Shanghai Jinpan Biotech Co Ltd 网站选购。

所有产品仅用作科学研究或药证申报，我们不为任何个人用途提供产品和服务

MMAF-OMe(Synonyms: Monomethyl auristatin F methyl ester)

发表于由

上海金畔生物科技有限公司为生命科学和医药研发人员提供生物活性分子抑制剂、激动剂、特异性抑制剂、化合物库、重组蛋白，专注于信号通路和疾病研究领域。

MMAF-OMe (Synonyms: Monomethyl auristatin F methyl ester) 纯度: 96.68%

MMAF-Ome 是一种 tubulin抑制剂，属于 ADC 的毒性分子，能够抑制 MDAMB435/5T4，MDAMB361DYT2，MDAMB468 和 Raji (5T4–) 这四种肿瘤细胞， IC50 值分别为 0.056 nM，0.166 nM，0.183 nM 和 0.449 nM。

MMAF-OMe(Synonyms: Monomethyl auristatin F methyl ester)

MMAF-OMe Chemical Structure

CAS No. : 863971-12-4

规格 价格 是否有货 数量
2 mg ￥2200 In-stock
5 mg ￥3500 In-stock
10 mg ￥5500 In-stock
50 mg   询价  
100 mg   询价  

* Please select Quantity before adding items.

MMAF-OMe 相关产品

•相关化合物库:

  • Bioactive Compound Library Plus
  • Toxins for Antibody-Drug Conjugate Research Library
  • Peptidomimetic Library

生物活性

MMAF-Ome, an antitubulin agent, is also an ADC cytotoxin. MMAF-Ome inhibits several tumor cell lines with IC50s of 0.056 nM, 0.166 nM, 0.183 nM, and 0.449 nM for MDAMB435/5T4, MDAMB361DYT2, MDAMB468, and Raji (5T4–) cell lines, respectively.

IC50 & Target

Auristatin

 

体外研究
(In Vitro)

2.5F-Fc and 2.5F-Fc-MMAF have similar IC50 values (6.9±1.1 vs. 8.3±1.3 nM, respectively), indicating that MMAF conjugation has negligible impact on integrin-binding affinity[1].

上海金畔生物科技有限公司 has not independently confirmed the accuracy of these methods. They are for reference only.
分子量

745.99

Formula

C40H67N5O8
CAS 号

863971-12-4
运输条件

Room temperature in continental US; may vary elsewhere.
储存方式
Powder -20°C 3 years
4°C 2 years

*该产品在溶液状态不稳定，建议您现用现配，即刻使用。
溶解性数据
In Vitro: 

DMSO : ≥ 100 mg/mL (134.05 mM)

* “≥” means soluble, but saturation unknown.

配制储备液
浓度 溶剂体积 质量 1 mg 5 mg 10 mg
1 mM 1.3405 mL 6.7025 mL 13.4050 mL
5 mM 0.2681 mL 1.3405 mL 2.6810 mL
10 mM 0.1341 mL 0.6703 mL 1.3405 mL

*

请根据产品在不同溶剂中的溶解度，选择合适的溶剂配制储备液；该产品在溶液状态不稳定，建议您现用现配，即刻使用。

In Vivo:

请根据您的实验动物和给药方式选择适当的溶解方案。以下溶解方案都请先按照 In Vitro 方式配制澄清的储备液，再依次添加助溶剂：

——为保证实验结果的可靠性，澄清的储备液可以根据储存条件，适当保存；体内实验的工作液，建议您现用现配，当天使用； 以下溶剂前显示的百
分比是指该溶剂在您配制终溶液中的体积占比；如在配制过程中出现沉淀、析出现象，可以通过加热和/或超声的方式助溶

  • 1.

    请依序添加每种溶剂： 10% DMSO    40% PEG300    5% Tween-80    45% saline

    Solubility: ≥ 2.5 mg/mL (3.35 mM); Clear solution

    此方案可获得 ≥ 2.5 mg/mL (3.35 mM，饱和度未知) 的澄清溶液。

    以 1 mL 工作液为例，取 100 μL 25.0 mg/mL 的澄清 DMSO 储备液加到 400 μL PEG300 中，混合均匀；向上述体系中加入50 μL Tween-80，混合均匀；然后继续加入 450 μL生理盐水定容至 1 mL。

    将 0.9 g 氯化钠，完全溶解于 100 mL ddH₂O 中，得到澄清透明的生理盐水溶液

  • 2.

    请依序添加每种溶剂： 10% DMSO    90% (20% SBE-β-CD in saline)

    Solubility: ≥ 2.5 mg/mL (3.35 mM); Clear solution

    此方案可获得 ≥ 2.5 mg/mL (3.35 mM，饱和度未知) 的澄清溶液。

    以 1 mL 工作液为例，取 100 μL 25.0 mg/mL 的澄清 DMSO 储备液加到 900 μL 20% 的 SBE-β-CD 生理盐水水溶液中，混合均匀。

    将 2 g 磺丁基醚 β-环糊精加入 5 mL 生理盐水中，再用生理盐水定容至 10 mL，完全溶解，澄清透明
  • 3.

    请依序添加每种溶剂： 10% DMSO    90% corn oil

    Solubility: ≥ 2.5 mg/mL (3.35 mM); Clear solution

    此方案可获得 ≥ 2.5 mg/mL (3.35 mM，饱和度未知) 的澄清溶液，此方案不适用于实验周期在半个月以上的实验。

    以 1 mL 工作液为例，取 100 μL 25.0 mg/mL 的澄清 DMSO 储备液加到 900 μL玉米油中，混合均匀。

*以上所有助溶剂都可在 上海金畔生物科技有限公司 网站选购。
参考文献

  • [1]. Currier NV, et al. Targeted Drug Delivery with an Integrin-Binding Knottin-Fc-MMAF Conjugate Produced by Cell-Free Protein Synthesis. Mol Cancer Ther. 2016 Jun;15(6):1291-300
Cell Assay
[1]

Cells are seeded in a 96-well plate at a density of 2,000 cells per well and grown overnight at 37°C, 5% CO2 in the media described for each cell line above. Cells are subsequently treated with 100 μL of fresh media, containing varying concentrations of knottin-Fc fusion proteins or linker-modified MMAF, and incubated for 5 days at 37°C, 5% CO2. Cell proliferation is measured using the Cell Counting Kit-8 (CCK-8), by adding the water-soluble tetrazolium salt, WST-8, to each well in an amount equal to 10% of the culture volume. After incubation for 1 hour at 37°C, absorbance at 450 nm is measured with a Synergy H4 microtiter plate reader. Cell proliferation is expressed as a percentage of absorbance relative to the control of untreated cells. Percent maximum proliferation is then reported as (sample − background)/(control − background) × 100. Error bars represent the SD of experiments performed in triplicate.

上海金畔生物科技有限公司 has not independently confirmed the accuracy of these methods. They are for reference only.
参考文献

  • [1]. Currier NV, et al. Targeted Drug Delivery with an Integrin-Binding Knottin-Fc-MMAF Conjugate Produced by Cell-Free Protein Synthesis. Mol Cancer Ther. 2016 Jun;15(6):1291-300

所有产品仅用作科学研究或药证申报，我们不为任何个人用途提供产品和服务

H-Hyp-OMe hydrochloride

发表于由

上海金畔生物科技有限公司为生命科学和医药研发人员提供生物活性分子抑制剂、激动剂、特异性抑制剂、化合物库、重组蛋白，专注于信号通路和疾病研究领域。

H-Hyp-OMe hydrochloride 

H-Hyp-OMe (hydrochloride) 是不可降解 (non-cleavable) 的 ADC linker，用于合成抗体偶联药物 (ADCs)。H-Hyp-OMe (hydrochloride) 也是一个基于烷基链 (alkyl chain) 的 PROTAC linker，可用于合成 PROTAC。

H-Hyp-OMe hydrochloride

H-Hyp-OMe hydrochloride Chemical Structure

CAS No. : 40216-83-9

规格 价格 是否有货 数量
1 g ￥500 In-stock
5 g ￥1000 In-stock
10 g   询价  
50 g   询价  

* Please select Quantity before adding items.

生物活性

H-Hyp-OMe hydrochloride is a non-cleavable ADC linker used in the synthesis of antibody-drug conjugates (ADCs). H-Hyp-OMe hydrochloride is also a alkyl chain-based PROTAC linker that can be used in the synthesis of PROTACs[1]<

IC50 & Target

Non-cleavable

 

体外研究
(In Vitro)

ADCs are comprised of an antibody to which is attached an ADC cytotoxin through an ADC linker[1].
PROTACs contain two different ligands connected by a linker; one is a ligand for an E3 ubiquitin ligase and the other is for the target protein. PROTACs exploit the intracellular ubiquitin-proteasome system to selectively degrade target proteins[2].

上海金畔生物科技有限公司 has not independently confirmed the accuracy of these methods. They are for reference only.
分子量

181.62

Formula

C6H12ClNO3
CAS 号

40216-83-9
运输条件

Room temperature in continental US; may vary elsewhere.
储存方式
Powder -20°C 3 years
4°C 2 years
In solvent -80°C 6 months
-20°C 1 month
参考文献

  • [1]. Beck A, et al. Strategies and challenges for the next generation of antibody-drug conjugates. Nat Rev Drug Discov. 2017;16(5):315-337.

    [2]. Nalawansha DA, et al. PROTACs: An Emerging Therapeutic Modality in Precision Medicine. Cell Chem Biol. 2020;27(8):998-985.

所有产品仅用作科学研究或药证申报，我们不为任何个人用途提供产品和服务

I-OMe-Tyrphostin AG 538(Synonyms: I-OMe-AG 538)

发表于由

上海金畔生物科技有限公司为生命科学和医药研发人员提供生物活性分子抑制剂、激动剂、特异性抑制剂、化合物库、重组蛋白，专注于信号通路和疾病研究领域。

I-OMe-Tyrphostin AG 538 (Synonyms: I-OMe-AG 538) 纯度: 99.34%

I-OMe-Tyrphostin AG 538 (I-OMe-AG 538) 是 IGF-1R 激酶的特异性抑制剂。I-OMe-Tyrphostin AG 538 抑制 IGF-1R 介导的信号传导，并优先对营养缺乏的 PANC1 细胞产生细胞毒性。I-OMe-Tyrphostin AG 538 是具有 ATP 竞争性的 PI5P4Kα抑制剂，IC50 为 1 μM。

I-OMe-Tyrphostin AG 538(Synonyms: I-OMe-AG 538)

I-OMe-Tyrphostin AG 538 Chemical Structure

CAS No. : 1094048-77-7

规格 价格 是否有货 数量
Free Sample (0.1-0.5 mg)   Apply now  
5 mg ￥1500 In-stock
10 mg ￥2500 In-stock
25 mg ￥5500 In-stock
50 mg ￥8500 In-stock
100 mg ￥13500 In-stock
200 mg   询价  
500 mg   询价  

* Please select Quantity before adding items.

I-OMe-Tyrphostin AG 538 相关产品

•相关化合物库:

  • Covalent Screening Library Plus
  • Bioactive Compound Library Plus
  • Kinase Inhibitor Library
  • Protein Tyrosine Kinase Compound Library
  • Anti-Cancer Compound Library
  • Anti-Aging Compound Library
  • Covalent Screening Library
  • Differentiation Inducing Compound Library
  • Anti-Pancreatic Cancer Compound Library
  • Angiogenesis Related Compound Library

生物活性

I-OMe-Tyrphostin AG 538 (I-OMe-AG 538) is a specific inhibitor of IGF-1R (insulin-like growth factor-1 receptor tyrosine kinase). I-OMe-Tyrphostin AG 538 inhibits IGF-1R-mediated signaling and is preferentially cytotoxic to nutrient-deprived PANC1 cells. I-OMe-Tyrphostin AG 538 is an ATP-competitive inhibitor of phosphatidylinositol-5-phosphate 4-kinase α (PI5P4Kα), with an IC50 of 1 µM[1].

IC50 & Target

IC50: 1 µM (PI5P4Kα)[1]
体外研究
(In Vitro)

I-OMe-Tyrphostin AG 538 (I-OMe-AG 538) (0.1-1000 µM; 24 hours) is cytotoxic to PANC-1 cells in nutrient-deprived medium[1].
I-OMe-Tyrphostin AG 538 (0-3 µM; 1 hour) blocks phosphorylation of IGF-1R, Akt and Erk[1].

上海金畔生物科技有限公司 has not independently confirmed the accuracy of these methods. They are for reference only.

Cell Viability Assay[1]

Cell Line: PANC-1 cells
Concentration: 0.1, 1, 10, 1000 µM
Incubation Time: 24 hours
Result: Cytotoxic to PANC-1 cells in nutrient-deprived medium.

Western Blot Analysis[1]

Cell Line: PANC-1 cells (stimulation with 50 ng/ml IGF-1 for 10 min)
Concentration: 0.03, 0.3, 3 µM
Incubation Time: 1 hour
Result: Blocked phosphorylation of IGF-1R, Akt and Erk.

分子量

437.19

Formula

C17H12INO5
CAS 号

1094048-77-7
运输条件

Room temperature in continental US; may vary elsewhere.
储存方式
Powder -20°C 3 years
4°C 2 years
In solvent -80°C 6 months
-20°C 1 month
溶解性数据
In Vitro: 

DMSO : 50 mg/mL (114.37 mM; Need ultrasonic)

配制储备液
浓度 溶剂体积 质量 1 mg 5 mg 10 mg
1 mM 2.2873 mL 11.4367 mL 22.8734 mL
5 mM 0.4575 mL 2.2873 mL 4.5747 mL
10 mM 0.2287 mL 1.1437 mL 2.2873 mL

*

请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。
储备液的保存方式和期限：-80°C, 6 months; -20°C, 1 month。-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。

In Vivo:

请根据您的实验动物和给药方式选择适当的溶解方案。以下溶解方案都请先按照 In Vitro 方式配制澄清的储备液，再依次添加助溶剂：

——为保证实验结果的可靠性，澄清的储备液可以根据储存条件，适当保存；体内实验的工作液，建议您现用现配，当天使用； 以下溶剂前显示的百
分比是指该溶剂在您配制终溶液中的体积占比；如在配制过程中出现沉淀、析出现象，可以通过加热和/或超声的方式助溶

  • 1.

    请依序添加每种溶剂： 10% DMSO    40% PEG300    5% Tween-80    45% saline

    Solubility: ≥ 2.5 mg/mL (5.72 mM); Clear solution

    此方案可获得 ≥ 2.5 mg/mL (5.72 mM，饱和度未知) 的澄清溶液。

    以 1 mL 工作液为例，取 100 μL 25.0 mg/mL 的澄清 DMSO 储备液加到 400 μL PEG300 中，混合均匀；向上述体系中加入50 μL Tween-80，混合均匀；然后继续加入 450 μL生理盐水定容至 1 mL。

    将 0.9 g 氯化钠，完全溶解于 100 mL ddH₂O 中，得到澄清透明的生理盐水溶液

  • 2.

    请依序添加每种溶剂： 10% DMSO    90% (20% SBE-β-CD in saline)

    Solubility: ≥ 2.5 mg/mL (5.72 mM); Clear solution

    此方案可获得 ≥ 2.5 mg/mL (5.72 mM，饱和度未知) 的澄清溶液。

    以 1 mL 工作液为例，取 100 μL 25.0 mg/mL 的澄清 DMSO 储备液加到 900 μL 20% 的 SBE-β-CD 生理盐水水溶液中，混合均匀。

    将 2 g 磺丁基醚 β-环糊精加入 5 mL 生理盐水中，再用生理盐水定容至 10 mL，完全溶解，澄清透明
*以上所有助溶剂都可在 上海金畔生物科技有限公司 网站选购。
参考文献

  • [1]. Davis MI, et al. A homogeneous, high-throughput assay for phosphatidylinositol 5-phosphate 4-kinase with a novel, rapid substrate preparation. PLoS One. 2013;8(1):e54127.

    [2]. Momose I, et al. Inhibitors of insulin-like growth factor-1 receptor tyrosine kinase are preferentially cytotoxic to nutrient-deprived pancreatic cancer cells. Biochem Biophys Res Commun. 2009 Feb 27;380(1):171-6.

所有产品仅用作科学研究或药证申报，我们不为任何个人用途提供产品和服务

Boc-Hyp-OMe

发表于由

上海金畔生物科技有限公司为生命科学和医药研发人员提供生物活性分子抑制剂、激动剂、特异性抑制剂、化合物库、重组蛋白，专注于信号通路和疾病研究领域。

Boc-Hyp-OMe 

Boc-Hyp-OMe 是不可降解 (non-cleavable) 的 ADC linker，用于合成抗体偶联药物 (ADCs)。Boc-Hyp-OMe 也是一个基于烷基链 (alkyl chain) 的 PROTAC linker，可用于合成 PROTAC。

Boc-Hyp-OMe

Boc-Hyp-OMe Chemical Structure

CAS No. : 74844-91-0

规格 价格 是否有货 数量
1 g ￥500 In-stock
5 g ￥1000 In-stock
10 g   询价  
50 g   询价  

* Please select Quantity before adding items.

生物活性

Boc-Hyp-OMe is a non-cleavable ADC linker used in the synthesis of antibody-drug conjugates (ADCs). Boc-Hyp-OMe is also a alkyl chain-based PROTAC linker that can be used in the synthesis of PROTACs[1][2].

IC50 & Target

Non-cleavable

 

体外研究
(In Vitro)

ADCs are comprised of an antibody to which is attached an ADC cytotoxin through an ADC linker[1].
PROTACs contain two different ligands connected by a linker; one is a ligand for an E3 ubiquitin ligase and the other is for the target protein. PROTACs exploit the intracellular ubiquitin-proteasome system to selectively degrade target proteins[2].

上海金畔生物科技有限公司 has not independently confirmed the accuracy of these methods. They are for reference only.
分子量

245.27

Formula

C11H19NO5
CAS 号

74844-91-0
运输条件

Room temperature in continental US; may vary elsewhere.
储存方式
Powder -20°C 3 years
4°C 2 years
In solvent -80°C 6 months
-20°C 1 month
参考文献

  • [1]. Beck A, et al. Strategies and challenges for the next generation of antibody-drug conjugates. Nat Rev Drug Discov. 2017;16(5):315-337.

    [2]. Nalawansha DA, et al. PROTACs: An Emerging Therapeutic Modality in Precision Medicine. Cell Chem Biol. 2020;27(8):998-985.

所有产品仅用作科学研究或药证申报，我们不为任何个人用途提供产品和服务

H-cis-Hyp-OMe hydrochloride

发表于由

上海金畔生物科技有限公司为生命科学和医药研发人员提供生物活性分子抑制剂、激动剂、特异性抑制剂、化合物库、重组蛋白，专注于信号通路和疾病研究领域。

H-cis-Hyp-OMe hydrochloride 

H-cis-Hyp-OMe hydrochloride 是不可降解 (non-cleavable) 的 ADC linker，用于合成抗体偶联药物 (ADCs)。H-cis-Hyp-OMe hydrochloride 也是一个基于烷基链 (alkyl chain) 的 PROTAC linker，可用于合成 PROTAC。

H-cis-Hyp-OMe hydrochloride

H-cis-Hyp-OMe hydrochloride Chemical Structure

CAS No. : 40126-30-5

规格 价格 是否有货 数量
1 g ￥400 In-stock
5 g ￥560 In-stock
10 g   询价  
50 g   询价  

* Please select Quantity before adding items.

生物活性

H-cis-Hyp-OMe hydrochloride is a non-cleavable ADC linker used in the synthesis of antibody-drug conjugates (ADCs). H-cis-Hyp-OMe hydrochloride is also a alkyl chain-based PROTAC linker that can be used in the synthesis of PR

IC50 & Target

Non-cleavable

 

体外研究
(In Vitro)

ADCs are comprised of an antibody to which is attached an ADC cytotoxin through an ADC linker[1].
PROTACs contain two different ligands connected by a linker; one is a ligand for an E3 ubiquitin ligase and the other is for the target protein. PROTACs exploit the intracellular ubiquitin-proteasome system to selectively degrade target proteins[2].

上海金畔生物科技有限公司 has not independently confirmed the accuracy of these methods. They are for reference only.
分子量

181.62

Formula

C6H12ClNO3
CAS 号

40126-30-5
运输条件

Room temperature in continental US; may vary elsewhere.
储存方式
Powder -20°C 3 years
4°C 2 years
In solvent -80°C 6 months
-20°C 1 month
参考文献

  • [1]. Beck A, et al. Strategies and challenges for the next generation of antibody-drug conjugates. Nat Rev Drug Discov. 2017;16(5):315-337.

    [2]. Nalawansha DA, et al. PROTACs: An Emerging Therapeutic Modality in Precision Medicine. Cell Chem Biol. 2020;27(8):998-985.

所有产品仅用作科学研究或药证申报，我们不为任何个人用途提供产品和服务

H-Arg(Pbf)-OMe hydrochloride

发表于由

上海金畔生物科技有限公司为生命科学和医药研发人员提供生物活性分子抑制剂、激动剂、特异性抑制剂、化合物库、重组蛋白，专注于信号通路和疾病研究领域。

H-Arg(Pbf)-OMe hydrochloride 

H-Arg(Pbf)-OMe hydrochloride 是一种精氨酸类似物，详细信息请参考专利 US20150197500A1 中的化合物 Arg-06。

H-Arg(Pbf)-OMe hydrochloride

H-Arg(Pbf)-OMe hydrochloride Chemical Structure

CAS No. : 257288-19-0

规格 是否有货
100 mg   询价  
250 mg   询价  
500 mg   询价  

* Please select Quantity before adding items.

生物活性

H-Arg(Pbf)-OMe hydrochloride is an arginine analogue extracted from patent US20150197500A1, Compound Arg-06[1].

分子量

477.02

Formula

C20H33ClN4O5S
CAS 号

257288-19-0
运输条件

Room temperature in continental US; may vary elsewhere.
储存方式

Please store the product under the recommended conditions in the Certificate of Analysis.
参考文献

  • [1]. John J. Talley, et al. No-releasing guanidine-chromene conjugates. US20150197500A1.

所有产品仅用作科学研究或药证申报，我们不为任何个人用途提供产品和服务

H-Arg(Pbf)-OMe hydrochloride

发表于由

上海金畔生物科技有限公司为生命科学和医药研发人员提供生物活性分子抑制剂、激动剂、特异性抑制剂、化合物库、重组蛋白，专注于信号通路和疾病研究领域。

H-Arg(Pbf)-OMe hydrochloride 

H-Arg(Pbf)-OMe hydrochloride 是一种精氨酸类似物，详细信息请参考专利 US20150197500A1 中的化合物 Arg-06。

H-Arg(Pbf)-OMe hydrochloride

H-Arg(Pbf)-OMe hydrochloride Chemical Structure

CAS No. : 257288-19-0

规格 是否有货
100 mg   询价  
250 mg   询价  
500 mg   询价  

* Please select Quantity before adding items.

生物活性

H-Arg(Pbf)-OMe hydrochloride is an arginine analogue extracted from patent US20150197500A1, Compound Arg-06[1].

分子量

477.02

Formula

C20H33ClN4O5S
CAS 号

257288-19-0
运输条件

Room temperature in continental US; may vary elsewhere.
储存方式

Please store the product under the recommended conditions in the Certificate of Analysis.
参考文献

  • [1]. John J. Talley, et al. No-releasing guanidine-chromene conjugates. US20150197500A1.

所有产品仅用作科学研究或药证申报，我们不为任何个人用途提供产品和服务

Dioxoisoindolin-O-PEG-OMe (MW 2000)(Synonyms: (1,3-dioxoisoindolin-2-yl)-O-PEG-OMe (MW 2000))

发表于由

上海金畔生物科技有限公司为生命科学和医药研发人员提供生物活性分子抑制剂、激动剂、特异性抑制剂、化合物库、重组蛋白，专注于信号通路和疾病研究领域。

Dioxoisoindolin-O-PEG-OMe (MW 2000) (Synonyms: (1,3-dioxoisoindolin-2-yl)-O-PEG-OMe (MW 2000))

Dioxoisoindolin-O-PEG-OMe (MW 2000) 是一种 PROTAC linker，属于 PEG 类。可用于合成 PROTAC 分子。

Dioxoisoindolin-O-PEG-OMe (MW 2000)(Synonyms: (1,3-dioxoisoindolin-2-yl)-O-PEG-OMe (MW 2000))

Dioxoisoindolin-O-PEG-OMe (MW 2000) Chemical Structure

规格 是否有货
100 mg   询价  
250 mg   询价  
500 mg   询价  

* Please select Quantity before adding items.

生物活性

Dioxoisoindolin-O-PEG-OMe (MW 2000) is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs[1].

IC50 & Target

PEGs

 

体外研究
(In Vitro)

PROTACs contain two different ligands connected by a linker; one is a ligand for an E3 ubiquitin ligase and the other is for the target protein. PROTACs exploit the intracellular ubiquitin-proteasome system to selectively degrade target proteins[1].

Shanghai Jinpan Biotech Co Ltd has not independently confirmed the accuracy of these methods. They are for reference only.
分子量

2000(Average)

运输条件

Room temperature in continental US; may vary elsewhere.
储存方式

Please store the product under the recommended conditions in the Certificate of Analysis.
参考文献

  • [1]. An S, et al. Small-molecule PROTACs: An emerging and promising approach for the development of targeted therapy drugs. EBioMedicine. 2018 Oct;36:553-562

所有产品仅用作科学研究或药证申报，我们不为任何个人用途提供产品和服务

Dioxoisoindolin-O-PEG-OMe (MW 2000)(Synonyms: (1,3-dioxoisoindolin-2-yl)-O-PEG-OMe (MW 2000))

发表于由

上海金畔生物科技有限公司为生命科学和医药研发人员提供生物活性分子抑制剂、激动剂、特异性抑制剂、化合物库、重组蛋白，专注于信号通路和疾病研究领域。

Dioxoisoindolin-O-PEG-OMe (MW 2000) (Synonyms: (1,3-dioxoisoindolin-2-yl)-O-PEG-OMe (MW 2000))

Dioxoisoindolin-O-PEG-OMe (MW 2000) 是一种 PROTAC linker，属于 PEG 类。可用于合成 PROTAC 分子。

Dioxoisoindolin-O-PEG-OMe (MW 2000)(Synonyms: (1,3-dioxoisoindolin-2-yl)-O-PEG-OMe (MW 2000))

Dioxoisoindolin-O-PEG-OMe (MW 2000) Chemical Structure

规格 是否有货
100 mg   询价  
250 mg   询价  
500 mg   询价  

* Please select Quantity before adding items.

生物活性

Dioxoisoindolin-O-PEG-OMe (MW 2000) is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs[1].

IC50 & Target

PEGs

 

体外研究
(In Vitro)

PROTACs contain two different ligands connected by a linker; one is a ligand for an E3 ubiquitin ligase and the other is for the target protein. PROTACs exploit the intracellular ubiquitin-proteasome system to selectively degrade target proteins[1].

Shanghai Jinpan Biotech Co Ltd has not independently confirmed the accuracy of these methods. They are for reference only.
分子量

2000(Average)

运输条件

Room temperature in continental US; may vary elsewhere.
储存方式

Please store the product under the recommended conditions in the Certificate of Analysis.
参考文献

  • [1]. An S, et al. Small-molecule PROTACs: An emerging and promising approach for the development of targeted therapy drugs. EBioMedicine. 2018 Oct;36:553-562

所有产品仅用作科学研究或药证申报，我们不为任何个人用途提供产品和服务

Z-LE(OMe)TD(OMe)-FMK

发表于由

上海金畔生物科技有限公司为生命科学和医药研发人员提供生物活性分子抑制剂、激动剂、特异性抑制剂、化合物库、重组蛋白，专注于信号通路和疾病研究领域。

Z-LE(OMe)TD(OMe)-FMK 

Z-LE(OMe)TD(OMe)-FMK 是一种选择性的 caspase-8 抑制剂，可以抑制细胞凋亡。

Z-LE(OMe)TD(OMe)-FMK

Z-LE(OMe)TD(OMe)-FMK Chemical Structure

CAS No. : 210344-93-7

规格 是否有货
100 mg   询价  
250 mg   询价  
500 mg   询价  

* Please select Quantity before adding items.

生物活性

Z-LE(OMe)TD(OMe)-FMK is a selective caspase-8 inhibitor. Z-LE(OMe)TD(OMe)-FMK can inhibit cell apoptosis[1].

体外研究
(In Vitro)

The apoptotic pathway activated after exposure of HL-60 cells to Cordycepin is caspase-8 dependent, because Z-LE(OMe)TD(OMe)-FMK partly inhibits endonucleosomal cleavage of DNA induced by cordycepin alone[1].

Shanghai Jinpan Biotech Co Ltd has not independently confirmed the accuracy of these methods. They are for reference only.
分子量

654.68

Formula

C30H43FN4O11
CAS 号

210344-93-7
运输条件

Room temperature in continental US; may vary elsewhere.
储存方式

Please store the product under the recommended conditions in the Certificate of Analysis.
参考文献

  • [1]. Hellinida Thomadaki, et al. The role of cordycepin in cancer treatment via induction or inhibition of apoptosis: implication of polyadenylation in a cell type specific manner. Cancer Chemother Pharmacol. 2008 Feb;61(2):251-65.

所有产品仅用作科学研究或药证申报，我们不为任何个人用途提供产品和服务

Z-LE(OMe)TD(OMe)-FMK

发表于由

上海金畔生物科技有限公司为生命科学和医药研发人员提供生物活性分子抑制剂、激动剂、特异性抑制剂、化合物库、重组蛋白，专注于信号通路和疾病研究领域。

Z-LE(OMe)TD(OMe)-FMK 

Z-LE(OMe)TD(OMe)-FMK 是一种选择性的 caspase-8 抑制剂，可以抑制细胞凋亡。

Z-LE(OMe)TD(OMe)-FMK

Z-LE(OMe)TD(OMe)-FMK Chemical Structure

CAS No. : 210344-93-7

规格 是否有货
100 mg   询价  
250 mg   询价  
500 mg   询价  

* Please select Quantity before adding items.

生物活性

Z-LE(OMe)TD(OMe)-FMK is a selective caspase-8 inhibitor. Z-LE(OMe)TD(OMe)-FMK can inhibit cell apoptosis[1].

体外研究
(In Vitro)

The apoptotic pathway activated after exposure of HL-60 cells to Cordycepin is caspase-8 dependent, because Z-LE(OMe)TD(OMe)-FMK partly inhibits endonucleosomal cleavage of DNA induced by cordycepin alone[1].

上海金畔生物科技有限公司 has not independently confirmed the accuracy of these methods. They are for reference only.
分子量

654.68

Formula

C30H43FN4O11
CAS 号

210344-93-7
运输条件

Room temperature in continental US; may vary elsewhere.
储存方式

Please store the product under the recommended conditions in the Certificate of Analysis.
参考文献

  • [1]. Hellinida Thomadaki, et al. The role of cordycepin in cancer treatment via induction or inhibition of apoptosis: implication of polyadenylation in a cell type specific manner. Cancer Chemother Pharmacol. 2008 Feb;61(2):251-65.

所有产品仅用作科学研究或药证申报，我们不为任何个人用途提供产品和服务

Z-LE(OMe)TD(OMe)-FMK

发表于由

上海金畔生物科技有限公司为生命科学和医药研发人员提供生物活性分子抑制剂、激动剂、特异性抑制剂、化合物库、重组蛋白，专注于信号通路和疾病研究领域。

Z-LE(OMe)TD(OMe)-FMK 

Z-LE(OMe)TD(OMe)-FMK 是一种选择性的 caspase-8 抑制剂，可以抑制细胞凋亡。

Z-LE(OMe)TD(OMe)-FMK

Z-LE(OMe)TD(OMe)-FMK Chemical Structure

CAS No. : 210344-93-7

规格 是否有货
100 mg   询价  
250 mg   询价  
500 mg   询价  

* Please select Quantity before adding items.

生物活性

Z-LE(OMe)TD(OMe)-FMK is a selective caspase-8 inhibitor. Z-LE(OMe)TD(OMe)-FMK can inhibit cell apoptosis[1].

体外研究
(In Vitro)

The apoptotic pathway activated after exposure of HL-60 cells to Cordycepin is caspase-8 dependent, because Z-LE(OMe)TD(OMe)-FMK partly inhibits endonucleosomal cleavage of DNA induced by cordycepin alone[1].

Shanghai Jinpan Biotech Co Ltd has not independently confirmed the accuracy of these methods. They are for reference only.
分子量

654.68

Formula

C30H43FN4O11
CAS 号

210344-93-7
运输条件

Room temperature in continental US; may vary elsewhere.
储存方式

Please store the product under the recommended conditions in the Certificate of Analysis.
参考文献

  • [1]. Hellinida Thomadaki, et al. The role of cordycepin in cancer treatment via induction or inhibition of apoptosis: implication of polyadenylation in a cell type specific manner. Cancer Chemother Pharmacol. 2008 Feb;61(2):251-65.

所有产品仅用作科学研究或药证申报，我们不为任何个人用途提供产品和服务

2′-OMe-G(ibu) Phosphoramidite

发表于由

上海金畔生物科技有限公司为生命科学和医药研发人员提供生物活性分子抑制剂、激动剂、特异性抑制剂、化合物库、重组蛋白，专注于信号通路和疾病研究领域。

2′-OMe-G(ibu) Phosphoramidite  纯度: 98.89%

2′-OMe-G(ibu) Phosphoramidite 是一种修饰过的亚磷酰胺单体，可用于寡核苷酸的合成。

2

2′-OMe-G(ibu) Phosphoramidite Chemical Structure

CAS No. : 150780-67-9

规格 价格 是否有货 数量
100 mg ￥500 In-stock
200 mg   询价  
500 mg   询价  

* Please select Quantity before adding items.

2′-OMe-G(ibu) Phosphoramidite 相关产品

•相关化合物库:

  • Bioactive Compound Library Plus
  • Anti-Infection Compound Library
  • Cell Cycle/DNA Damage Compound Library
  • Anti-Cancer Compound Library
  • Anti-Aging Compound Library
  • Reprogramming Compound Library
  • Nucleotide Compound Library
  • Anti-Lung Cancer Compound Library
  • Anti-Blood Cancer Compound Library
  • Anti-Cancer Metabolism Compound Library

生物活性

2′-OMe-G(ibu) Phosphoramidite is a modified phosphoramidite monomer, which can be used for the oligonucleotide synthesis.

分子量

869.94

Formula

C45H56N7O9P
CAS 号

150780-67-9
运输条件

Room temperature in continental US; may vary elsewhere.
储存方式

4°C, protect from light

*In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)
溶解性数据
In Vitro: 

DMSO : 100 mg/mL (114.95 mM; Need ultrasonic)

配制储备液
浓度 溶剂体积 质量 1 mg 5 mg 10 mg
1 mM 1.1495 mL 5.7475 mL 11.4950 mL
5 mM 0.2299 mL 1.1495 mL 2.2990 mL
10 mM 0.1150 mL 0.5748 mL 1.1495 mL

*

请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。
储备液的保存方式和期限：-80°C, 6 months; -20°C, 1 month (protect from light)。-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。

In Vivo:

请根据您的实验动物和给药方式选择适当的溶解方案。以下溶解方案都请先按照 In Vitro 方式配制澄清的储备液，再依次添加助溶剂：

——为保证实验结果的可靠性，澄清的储备液可以根据储存条件，适当保存；体内实验的工作液，建议您现用现配，当天使用； 以下溶剂前显示的百
分比是指该溶剂在您配制终溶液中的体积占比；如在配制过程中出现沉淀、析出现象，可以通过加热和/或超声的方式助溶

  • 1.

    请依序添加每种溶剂： 10% DMSO    40% PEG300    5% Tween-80    45% saline

    Solubility: ≥ 2.5 mg/mL (2.87 mM); Clear solution

    此方案可获得 ≥ 2.5 mg/mL (2.87 mM，饱和度未知) 的澄清溶液。

    以 1 mL 工作液为例，取 100 μL 25.0 mg/mL 的澄清 DMSO 储备液加到 400 μL PEG300 中，混合均匀；向上述体系中加入50 μL Tween-80，混合均匀；然后继续加入 450 μL生理盐水定容至 1 mL。

    将 0.9 g 氯化钠，完全溶解于 100 mL ddH₂O 中，得到澄清透明的生理盐水溶液

  • 2.

    请依序添加每种溶剂： 10% DMSO    90% corn oil

    Solubility: ≥ 2.5 mg/mL (2.87 mM); Clear solution

    此方案可获得 ≥ 2.5 mg/mL (2.87 mM，饱和度未知) 的澄清溶液，此方案不适用于实验周期在半个月以上的实验。

    以 1 mL 工作液为例，取 100 μL 25.0 mg/mL 的澄清 DMSO 储备液加到 900 μL玉米油中，混合均匀。

*以上所有助溶剂都可在 Shanghai Jinpan Biotech Co Ltd 网站选购。

所有产品仅用作科学研究或药证申报，我们不为任何个人用途提供产品和服务

2′-OMe-G(ibu) Phosphoramidite

发表于由

上海金畔生物科技有限公司为生命科学和医药研发人员提供生物活性分子抑制剂、激动剂、特异性抑制剂、化合物库、重组蛋白，专注于信号通路和疾病研究领域。

2′-OMe-G(ibu) Phosphoramidite  纯度: 98.89%

2′-OMe-G(ibu) Phosphoramidite 是一种修饰过的亚磷酰胺单体，可用于寡核苷酸的合成。

2

2′-OMe-G(ibu) Phosphoramidite Chemical Structure

CAS No. : 150780-67-9

规格 价格 是否有货 数量
100 mg ￥500 In-stock
200 mg   询价  
500 mg   询价  

* Please select Quantity before adding items.

2′-OMe-G(ibu) Phosphoramidite 相关产品

•相关化合物库:

  • Bioactive Compound Library Plus
  • Anti-Infection Compound Library
  • Cell Cycle/DNA Damage Compound Library
  • Anti-Cancer Compound Library
  • Anti-Aging Compound Library
  • Reprogramming Compound Library
  • Nucleotide Compound Library
  • Anti-Lung Cancer Compound Library
  • Anti-Blood Cancer Compound Library
  • Anti-Cancer Metabolism Compound Library

生物活性

2′-OMe-G(ibu) Phosphoramidite is a modified phosphoramidite monomer, which can be used for the oligonucleotide synthesis.

分子量

869.94

Formula

C45H56N7O9P
CAS 号

150780-67-9
运输条件

Room temperature in continental US; may vary elsewhere.
储存方式

4°C, protect from light

*In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)
溶解性数据
In Vitro: 

DMSO : 100 mg/mL (114.95 mM; Need ultrasonic)

配制储备液
浓度 溶剂体积 质量 1 mg 5 mg 10 mg
1 mM 1.1495 mL 5.7475 mL 11.4950 mL
5 mM 0.2299 mL 1.1495 mL 2.2990 mL
10 mM 0.1150 mL 0.5748 mL 1.1495 mL

*

请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。
储备液的保存方式和期限：-80°C, 6 months; -20°C, 1 month (protect from light)。-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。

In Vivo:

请根据您的实验动物和给药方式选择适当的溶解方案。以下溶解方案都请先按照 In Vitro 方式配制澄清的储备液，再依次添加助溶剂：

——为保证实验结果的可靠性，澄清的储备液可以根据储存条件，适当保存；体内实验的工作液，建议您现用现配，当天使用； 以下溶剂前显示的百
分比是指该溶剂在您配制终溶液中的体积占比；如在配制过程中出现沉淀、析出现象，可以通过加热和/或超声的方式助溶

  • 1.

    请依序添加每种溶剂： 10% DMSO    40% PEG300    5% Tween-80    45% saline

    Solubility: ≥ 2.5 mg/mL (2.87 mM); Clear solution

    此方案可获得 ≥ 2.5 mg/mL (2.87 mM，饱和度未知) 的澄清溶液。

    以 1 mL 工作液为例，取 100 μL 25.0 mg/mL 的澄清 DMSO 储备液加到 400 μL PEG300 中，混合均匀；向上述体系中加入50 μL Tween-80，混合均匀；然后继续加入 450 μL生理盐水定容至 1 mL。

    将 0.9 g 氯化钠，完全溶解于 100 mL ddH₂O 中，得到澄清透明的生理盐水溶液

  • 2.

    请依序添加每种溶剂： 10% DMSO    90% corn oil

    Solubility: ≥ 2.5 mg/mL (2.87 mM); Clear solution

    此方案可获得 ≥ 2.5 mg/mL (2.87 mM，饱和度未知) 的澄清溶液，此方案不适用于实验周期在半个月以上的实验。

    以 1 mL 工作液为例，取 100 μL 25.0 mg/mL 的澄清 DMSO 储备液加到 900 μL玉米油中，混合均匀。

*以上所有助溶剂都可在 Shanghai Jinpan Biotech Co Ltd 网站选购。

所有产品仅用作科学研究或药证申报，我们不为任何个人用途提供产品和服务

2′-OMe-G(ibu) Phosphoramidite

发表于由

上海金畔生物科技有限公司为生命科学和医药研发人员提供生物活性分子抑制剂、激动剂、特异性抑制剂、化合物库、重组蛋白，专注于信号通路和疾病研究领域。

2′-OMe-G(ibu) Phosphoramidite  纯度: 98.89%

2′-OMe-G(ibu) Phosphoramidite 是一种修饰过的亚磷酰胺单体，可用于寡核苷酸的合成。

2

2′-OMe-G(ibu) Phosphoramidite Chemical Structure

CAS No. : 150780-67-9

规格 价格 是否有货 数量
100 mg ￥500 In-stock
200 mg   询价  
500 mg   询价  

* Please select Quantity before adding items.

2′-OMe-G(ibu) Phosphoramidite 相关产品

•相关化合物库:

  • Bioactive Compound Library Plus
  • Anti-Infection Compound Library
  • Cell Cycle/DNA Damage Compound Library
  • Anti-Cancer Compound Library
  • Anti-Aging Compound Library
  • Reprogramming Compound Library
  • Nucleotide Compound Library
  • Anti-Lung Cancer Compound Library
  • Anti-Blood Cancer Compound Library
  • Anti-Cancer Metabolism Compound Library

生物活性

2′-OMe-G(ibu) Phosphoramidite is a modified phosphoramidite monomer, which can be used for the oligonucleotide synthesis.

分子量

869.94

Formula

C45H56N7O9P
CAS 号

150780-67-9
运输条件

Room temperature in continental US; may vary elsewhere.
储存方式

4°C, protect from light

*In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)
溶解性数据
In Vitro: 

DMSO : 100 mg/mL (114.95 mM; Need ultrasonic)

配制储备液
浓度 溶剂体积 质量 1 mg 5 mg 10 mg
1 mM 1.1495 mL 5.7475 mL 11.4950 mL
5 mM 0.2299 mL 1.1495 mL 2.2990 mL
10 mM 0.1150 mL 0.5748 mL 1.1495 mL

*

请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。
储备液的保存方式和期限：-80°C, 6 months; -20°C, 1 month (protect from light)。-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。

In Vivo:

请根据您的实验动物和给药方式选择适当的溶解方案。以下溶解方案都请先按照 In Vitro 方式配制澄清的储备液，再依次添加助溶剂：

——为保证实验结果的可靠性，澄清的储备液可以根据储存条件，适当保存；体内实验的工作液，建议您现用现配，当天使用； 以下溶剂前显示的百
分比是指该溶剂在您配制终溶液中的体积占比；如在配制过程中出现沉淀、析出现象，可以通过加热和/或超声的方式助溶

  • 1.

    请依序添加每种溶剂： 10% DMSO    40% PEG300    5% Tween-80    45% saline

    Solubility: ≥ 2.5 mg/mL (2.87 mM); Clear solution

    此方案可获得 ≥ 2.5 mg/mL (2.87 mM，饱和度未知) 的澄清溶液。

    以 1 mL 工作液为例，取 100 μL 25.0 mg/mL 的澄清 DMSO 储备液加到 400 μL PEG300 中，混合均匀；向上述体系中加入50 μL Tween-80，混合均匀；然后继续加入 450 μL生理盐水定容至 1 mL。

    将 0.9 g 氯化钠，完全溶解于 100 mL ddH₂O 中，得到澄清透明的生理盐水溶液

  • 2.

    请依序添加每种溶剂： 10% DMSO    90% corn oil

    Solubility: ≥ 2.5 mg/mL (2.87 mM); Clear solution

    此方案可获得 ≥ 2.5 mg/mL (2.87 mM，饱和度未知) 的澄清溶液，此方案不适用于实验周期在半个月以上的实验。

    以 1 mL 工作液为例，取 100 μL 25.0 mg/mL 的澄清 DMSO 储备液加到 900 μL玉米油中，混合均匀。

*以上所有助溶剂都可在 上海金畔生物科技有限公司 网站选购。

所有产品仅用作科学研究或药证申报，我们不为任何个人用途提供产品和服务